Skip to content

Effects of esketamine on perioperative anxiety and depression in patients undergoing thoracoscopic pulmonary nodule resection

Effects of esketamine on perioperative anxiety and depression in patients undergoing thoracoscopic pulmonary nodule resection

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055232
Enrollment
Unknown
Registered
2022-01-03
Start date
2021-04-20
Completion date
Unknown
Last updated
2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anxiety, depression

Interventions

low-dose eskatemine group:eskatemine 0.25mg/kg
control group:normal saline

Sponsors

Changzhou NO.2 People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients with pulmonary nodule undergoing thoracoscopic surgery; 2.Aged 18 to 80 years, gender unlimited, ASA grade I ~ III; 3.No history of serious mental illness or psychotropic drug use; 4.have a middle school degree at lest; 5.The hospital stay was longer than 5 days.

Exclusion criteria

Exclusion criteria: 1.Patients with history of mental disorders or under treatment of psychotropic drug; 2.Patients with drug,alcohol or opioid abuse; 3.Patients with poorly controlled or untreated hypertension; 4.Patients with coronary heart disease; 5.Patients with hyperthyroidism; 6.Patients with serious heart ,brain ,liver,kidney or blood disease.

Design outcomes

Primary

MeasureTime frame
SAS and SDS score;VAS score;

Secondary

MeasureTime frame
quality of recovery, QoR-15;length of hospital stay;postoperative complications;

Countries

China

Contacts

Public ContactWu Zhouquan

Changzhou NO.2 People's Hospital

luyanfeng367@163.com+86 13585357393

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026